Replay Holdings LLC and The University of Texas MD Anderson Cancer Center report that the FDA has cleared the IND application for PRAME TCR/IL-15 NK (SY-307), an engineered T-cell receptor natural killer (TCR-NK) cell therapy for relapsed/refractory myeloid malignancies.
Accession Therapeutics Ltd. has raised £25 million (US$31.3 million) to fund it through the generation of the first clinical data for its lead product, TROCEPT-01 (ATTR-01), and completion of IND-enabling studies for a second program. The internal early-stage pipeline will also be progressed.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.
Space Liintech Co. Ltd., of Daejeon, South Korea, raised ₩4 billion (US$2.9 million) in a series A financing round to advance new drug research, development and production in outer space, as the private sector races to harness the orbit for pharmaceutical experiments.
Epidermal growth factor receptor (EGFR) is widely expressed among multiple cancer types, but patients often develop resistance to EGFR tyrosine kinase inhibitors (TKIs), which may be accompanied by increased expression of CD70.
Hookipa Pharma Inc. has received clearance from the U.S. FDA for its IND application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The HB-700 program is a replicating 2-vector therapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers by targeting the five most prevalent KRAS mutations in these disease indications.
Shanghai De Novo Pharmatech Co. Ltd. has described antibody-immunostimulatory conjugates consisting of an antibody covalently bound to Toll-like receptor 8 (TLR8) agonists through a linker reported to be useful for the treatment of cancer.
Arbutus Biopharma Corp. has divulged programmed cell death protein 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, hepatitis B and hepatitis D infections.
Multiple myeloma (MM) is still an uncurable disease. Chimeric antigen receptor (CAR) T cells directed to tumor necrosis factor receptor superfamily member 17, also known as BCMA, have transformed the field, with high response rate and durable remissions, but the access to this therapy is limited by multiple factors.
The FDA has cleared Oncoc4 Inc.’s IND application for ONC-841, a potential first-in-class Siglec-10-blocking antibody for the treatment of solid tumors.
RSS
